...
首页> 外文期刊>Journal of Medicinal Chemistry >Identification and characterization of small molecules as potent and specific EPAC2 antagonists
【24h】

Identification and characterization of small molecules as potent and specific EPAC2 antagonists

机译:鉴定和表征作为有效和特异性EPAC2拮抗剂的小分子

获取原文
获取原文并翻译 | 示例

摘要

EPAC1 and EPAC2, two isoforms of exchange proteins directly activated by cAMP (EPAC), respond to the second messenger cAMP and regulate a wide variety of intracellular processes under physiological and pathophysiological circumstances. Herein, we report the chemical design, synthesis, and pharmacological characterization of three different scaffolds (diarylsulfones, N,N-diarylamines, and arylsulfonamides) as highly potent and selective antagonists of EPAC2. Several selective EPAC2 antagonists have been identified including 20i (HJC0350), which has an apparent IC_(50) of 0.3 μM for competing with 8-NBD-cAMP binding of EPAC2 and is about 133-fold more potent than cAMP. Compounds 1 (ESI-05), 14c (HJC0338), and 20i, selected from each series, have exhibited no inhibition of EPAC1-mediated Rap1-GDP exchange activity at 25 μM, indicating that they are EPAC2-specific antagonists. Moreover, live-cell imaging studies using EPAC1, EPAC2, or PKA FRET sensor also demonstrate that 20i functions as an EPAC2 specific antagonist.
机译:EPAC1和EPAC2是被cAMP(EPAC)直接激活的两种交换蛋白同工型,在生理和病理生理情况下,对第二个信使cAMP作出反应并调节多种细胞内过程。在本文中,我们报告了作为EPAC2高效和选择性拮抗剂的三种不同支架(二芳基砜,N,N-二芳基胺和芳基磺酰胺)的化学设计,合成和药理学表征。已经鉴定出几种选择性的EPAC2拮抗剂,包括20i(HJC0350),其与EPAC2的8-NBD-cAMP结合竞争的表观IC_(50)为0.3μM,效力比cAMP高约133倍。从每个系列中选择的化合物1(ESI-05),14c(HJC0338)和20i在25μM浓度下均未显示EPAC1介导的Rap1-GDP交换活性的抑制作用,表明它们是EPAC2特异性拮抗剂。此外,使用EPAC1,EPAC2或PKA FRET传感器进行的活细胞成像研究还表明20i可以作为EPAC2特异性拮抗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号